Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome.

Giuseppe Vezzoli, Teresa Arcidiacono, Vera Paloschi, Annalisa Terranegra, Rita Biasion, Giovanna Weber, Stefano Mora, Marie Louise Syren, Domenico Coviello, Daniele Cusi, Giuseppe Bianchi, Laura Soldati

Research output: Contribution to journalArticle

Abstract

Type 5 Bartter syndrome has been recently defined as a Bartter syndrome due to the most activating mutations of the calcium-sensing receptor (CaSR). It has been attributed to the inhibition exerted by CaSR activity on sodium transport in the thick ascending limb of the loop of Henle (TALH). Two monozygotic twin sisters (T1 and T2) with autosomal dominant hypocalcemia (ADH) due to a nonconservative activating CaSR mutation in the extracellular domain (K29E) were studied. They developed a Bartter-like syndrome characterized by a mild phenotype: hypokalemia occurred only at the age of 22 years; it was corrected with small doses of oral potassium in one twin, while the other twin needed no potassium supplements to maintain borderline levels of plasma potassium; alkalosis was absent; plasma renin and aldosterone production were not markedly activated. Furthermore, the natriuretic response to furosemide, a inhibitor of sodium reabsorption in the TALH, was conserved in both twins. The K29E mutation was previously reported as one of the most activating mutations of the CaSR gene leading to a very marked increase in CaSR sensitivity to calcium ions. These findings confirm that Bartter syndrome is typically associated with ADH provided that the underlying mutation of CaSR is able to produce a conspicuous gain of function. However, the phenotype of type 5 Bartter syndrome may manifest with variable severity, not directly related with the in vitro potency of the CaSR activating mutation.

Original languageEnglish
Pages (from-to)525-528
Number of pages4
JournalJournal of Nephrology
Volume19
Issue number4
Publication statusPublished - Jul 2006
Externally publishedYes

Fingerprint

Bartter Syndrome
Calcium-Sensing Receptors
Mutation
Loop of Henle
Potassium
Sodium
Phenotype
Alkalosis
Hypokalemia
Monozygotic Twins
Furosemide
Familial Hypercalciuric Hypocalcemia
Aldosterone
Renin
Siblings
Ions
Calcium

ASJC Scopus subject areas

  • Nephrology

Cite this

Vezzoli, G., Arcidiacono, T., Paloschi, V., Terranegra, A., Biasion, R., Weber, G., ... Soldati, L. (2006). Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome. Journal of Nephrology, 19(4), 525-528.

Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome. / Vezzoli, Giuseppe; Arcidiacono, Teresa; Paloschi, Vera; Terranegra, Annalisa; Biasion, Rita; Weber, Giovanna; Mora, Stefano; Syren, Marie Louise; Coviello, Domenico; Cusi, Daniele; Bianchi, Giuseppe; Soldati, Laura.

In: Journal of Nephrology, Vol. 19, No. 4, 07.2006, p. 525-528.

Research output: Contribution to journalArticle

Vezzoli, G, Arcidiacono, T, Paloschi, V, Terranegra, A, Biasion, R, Weber, G, Mora, S, Syren, ML, Coviello, D, Cusi, D, Bianchi, G & Soldati, L 2006, 'Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome.', Journal of Nephrology, vol. 19, no. 4, pp. 525-528.
Vezzoli G, Arcidiacono T, Paloschi V, Terranegra A, Biasion R, Weber G et al. Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome. Journal of Nephrology. 2006 Jul;19(4):525-528.
Vezzoli, Giuseppe ; Arcidiacono, Teresa ; Paloschi, Vera ; Terranegra, Annalisa ; Biasion, Rita ; Weber, Giovanna ; Mora, Stefano ; Syren, Marie Louise ; Coviello, Domenico ; Cusi, Daniele ; Bianchi, Giuseppe ; Soldati, Laura. / Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome. In: Journal of Nephrology. 2006 ; Vol. 19, No. 4. pp. 525-528.
@article{8416d22764b748e49f8784b80ce497b8,
title = "Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome.",
abstract = "Type 5 Bartter syndrome has been recently defined as a Bartter syndrome due to the most activating mutations of the calcium-sensing receptor (CaSR). It has been attributed to the inhibition exerted by CaSR activity on sodium transport in the thick ascending limb of the loop of Henle (TALH). Two monozygotic twin sisters (T1 and T2) with autosomal dominant hypocalcemia (ADH) due to a nonconservative activating CaSR mutation in the extracellular domain (K29E) were studied. They developed a Bartter-like syndrome characterized by a mild phenotype: hypokalemia occurred only at the age of 22 years; it was corrected with small doses of oral potassium in one twin, while the other twin needed no potassium supplements to maintain borderline levels of plasma potassium; alkalosis was absent; plasma renin and aldosterone production were not markedly activated. Furthermore, the natriuretic response to furosemide, a inhibitor of sodium reabsorption in the TALH, was conserved in both twins. The K29E mutation was previously reported as one of the most activating mutations of the CaSR gene leading to a very marked increase in CaSR sensitivity to calcium ions. These findings confirm that Bartter syndrome is typically associated with ADH provided that the underlying mutation of CaSR is able to produce a conspicuous gain of function. However, the phenotype of type 5 Bartter syndrome may manifest with variable severity, not directly related with the in vitro potency of the CaSR activating mutation.",
author = "Giuseppe Vezzoli and Teresa Arcidiacono and Vera Paloschi and Annalisa Terranegra and Rita Biasion and Giovanna Weber and Stefano Mora and Syren, {Marie Louise} and Domenico Coviello and Daniele Cusi and Giuseppe Bianchi and Laura Soldati",
year = "2006",
month = "7",
language = "English",
volume = "19",
pages = "525--528",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Wichtig Publishing",
number = "4",

}

TY - JOUR

T1 - Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome.

AU - Vezzoli, Giuseppe

AU - Arcidiacono, Teresa

AU - Paloschi, Vera

AU - Terranegra, Annalisa

AU - Biasion, Rita

AU - Weber, Giovanna

AU - Mora, Stefano

AU - Syren, Marie Louise

AU - Coviello, Domenico

AU - Cusi, Daniele

AU - Bianchi, Giuseppe

AU - Soldati, Laura

PY - 2006/7

Y1 - 2006/7

N2 - Type 5 Bartter syndrome has been recently defined as a Bartter syndrome due to the most activating mutations of the calcium-sensing receptor (CaSR). It has been attributed to the inhibition exerted by CaSR activity on sodium transport in the thick ascending limb of the loop of Henle (TALH). Two monozygotic twin sisters (T1 and T2) with autosomal dominant hypocalcemia (ADH) due to a nonconservative activating CaSR mutation in the extracellular domain (K29E) were studied. They developed a Bartter-like syndrome characterized by a mild phenotype: hypokalemia occurred only at the age of 22 years; it was corrected with small doses of oral potassium in one twin, while the other twin needed no potassium supplements to maintain borderline levels of plasma potassium; alkalosis was absent; plasma renin and aldosterone production were not markedly activated. Furthermore, the natriuretic response to furosemide, a inhibitor of sodium reabsorption in the TALH, was conserved in both twins. The K29E mutation was previously reported as one of the most activating mutations of the CaSR gene leading to a very marked increase in CaSR sensitivity to calcium ions. These findings confirm that Bartter syndrome is typically associated with ADH provided that the underlying mutation of CaSR is able to produce a conspicuous gain of function. However, the phenotype of type 5 Bartter syndrome may manifest with variable severity, not directly related with the in vitro potency of the CaSR activating mutation.

AB - Type 5 Bartter syndrome has been recently defined as a Bartter syndrome due to the most activating mutations of the calcium-sensing receptor (CaSR). It has been attributed to the inhibition exerted by CaSR activity on sodium transport in the thick ascending limb of the loop of Henle (TALH). Two monozygotic twin sisters (T1 and T2) with autosomal dominant hypocalcemia (ADH) due to a nonconservative activating CaSR mutation in the extracellular domain (K29E) were studied. They developed a Bartter-like syndrome characterized by a mild phenotype: hypokalemia occurred only at the age of 22 years; it was corrected with small doses of oral potassium in one twin, while the other twin needed no potassium supplements to maintain borderline levels of plasma potassium; alkalosis was absent; plasma renin and aldosterone production were not markedly activated. Furthermore, the natriuretic response to furosemide, a inhibitor of sodium reabsorption in the TALH, was conserved in both twins. The K29E mutation was previously reported as one of the most activating mutations of the CaSR gene leading to a very marked increase in CaSR sensitivity to calcium ions. These findings confirm that Bartter syndrome is typically associated with ADH provided that the underlying mutation of CaSR is able to produce a conspicuous gain of function. However, the phenotype of type 5 Bartter syndrome may manifest with variable severity, not directly related with the in vitro potency of the CaSR activating mutation.

UR - http://www.scopus.com/inward/record.url?scp=33750861259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750861259&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 525

EP - 528

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 4

ER -